HAL-MPE1 / HAL Allergy - LARVOL DELTA

HAL-MPE1, a novel subcutaneous immunotherapy candidate for peanut allergy. Phase I randomized placebo-controlled study (EAACI 2026) - "Background Following withdrawal of Palforzia, patients with peanut allergy lack disease-modifying treatment options. Specific- IgG4 increase was most pronounced in the cohort of children: In children (median age 9 years), total IgG4 GMFI reached 5.19 at study end (p<0.0001). Conclusion HAL-MPE1 demonstrated acceptable tolerability across all age groups and robust induction of peanut-specific IgG4 within 16–21 weeks treatment, supporting further clinical development of SCIT for peanut allergy."

Clinical • Late-breaking abstract • P1 data • Allergy • Food Hypersensitivity • Immunology

HAL-MPE1 Safety and Tolerability Study (clinicaltrials.gov) - P1; N=42; Completed; Sponsor: HAL Allergy; Active, not recruiting ➔ Completed

Trial completion